PL3786160T3 - Pochodne pirydyny i ich zastosowania terapeutyczne jako inhibitory trpc6 - Google Patents

Pochodne pirydyny i ich zastosowania terapeutyczne jako inhibitory trpc6

Info

Publication number
PL3786160T3
PL3786160T3 PL20197194.2T PL20197194T PL3786160T3 PL 3786160 T3 PL3786160 T3 PL 3786160T3 PL 20197194 T PL20197194 T PL 20197194T PL 3786160 T3 PL3786160 T3 PL 3786160T3
Authority
PL
Poland
Prior art keywords
therapeutic uses
pyridine derivatives
trpc6
inhibitors
trpc6 inhibitors
Prior art date
Application number
PL20197194.2T
Other languages
English (en)
Inventor
Thierry Bouyssou
Dirk Gottschling
Niklas Heine
Lana Louise Smith Keenan
Michael D. Lowe
Hossein Razavi
Christopher Ronald Sarko
Simon Surprenant
Hidenori Takahashi
Michael Robert Turner
Xinyuan Wu
Original Assignee
Boehringer Ingelheim International Gmbh
Hydra Biosciences, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Hydra Biosciences, Llc filed Critical Boehringer Ingelheim International Gmbh
Publication of PL3786160T3 publication Critical patent/PL3786160T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL20197194.2T 2017-10-27 2018-10-25 Pochodne pirydyny i ich zastosowania terapeutyczne jako inhibitory trpc6 PL3786160T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762577883P 2017-10-27 2017-10-27
US201862628313P 2018-02-09 2018-02-09

Publications (1)

Publication Number Publication Date
PL3786160T3 true PL3786160T3 (pl) 2022-10-24

Family

ID=64270818

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20197194.2T PL3786160T3 (pl) 2017-10-27 2018-10-25 Pochodne pirydyny i ich zastosowania terapeutyczne jako inhibitory trpc6
PL18800513.6T PL3700902T3 (pl) 2017-10-27 2018-10-25 Inhibitory trpc6

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18800513.6T PL3700902T3 (pl) 2017-10-27 2018-10-25 Inhibitory trpc6

Country Status (31)

Country Link
US (4) US10889568B2 (pl)
EP (2) EP3700902B8 (pl)
JP (2) JP7217273B6 (pl)
KR (2) KR20200125758A (pl)
CN (1) CN111527078B (pl)
AU (2) AU2018355743B2 (pl)
CA (1) CA3078769A1 (pl)
CL (2) CL2020001097A1 (pl)
CY (1) CY1126109T1 (pl)
DK (2) DK3786160T3 (pl)
ES (2) ES2946274T3 (pl)
FI (1) FI3700902T3 (pl)
HR (2) HRP20220991T1 (pl)
HU (2) HUE059450T2 (pl)
IL (2) IL274039B (pl)
LT (2) LT3786160T (pl)
MX (1) MX387232B (pl)
MY (1) MY202126A (pl)
NZ (1) NZ763816A (pl)
PE (1) PE20210154A1 (pl)
PH (1) PH12020550503A1 (pl)
PL (2) PL3786160T3 (pl)
PT (2) PT3700902T (pl)
RS (2) RS64271B1 (pl)
SA (1) SA520411843B1 (pl)
SG (2) SG10202011632RA (pl)
SI (2) SI3700902T1 (pl)
TW (2) TWI780246B (pl)
UA (1) UA128474C2 (pl)
WO (1) WO2019081637A1 (pl)
ZA (1) ZA202002372B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3786160T3 (pl) * 2017-10-27 2022-10-24 Boehringer Ingelheim International Gmbh Pochodne pirydyny i ich zastosowania terapeutyczne jako inhibitory trpc6
CN111770918B (zh) * 2018-02-15 2024-02-27 勃林格殷格翰国际公司 Trpc6的抑制剂
EP3752503A1 (en) * 2018-02-16 2020-12-23 Boehringer Ingelheim International GmbH Inhibitors of trpc6
IL315313A (en) * 2018-08-24 2024-10-01 Xeniopro GmbH Aromatic molecules for use in the treatment of pathological conditions
CN113677673B (zh) * 2019-04-12 2024-03-05 勃林格殷格翰国际有限公司 Trpc6的抑制剂
WO2021079962A1 (ja) * 2019-10-24 2021-04-29 国立大学法人大阪大学 難聴の予防および／または治療用医薬組成物
US20230137816A1 (en) 2020-02-11 2023-05-04 Deutsches Herzzentrum Muenchen Des Freistaates Bayern Administration of calcium channel trpc6 inhibitors using balloons, stents or other medical devices
AR121846A1 (es) * 2020-04-16 2022-07-13 Teijin Pharma Ltd Derivado de arilo o heteroarilo
US20230149393A1 (en) * 2020-04-16 2023-05-18 Boehringer Ingelheim International Gmbh Inhibitors of trpc6 for treating respiratory conditions
CN113105318B (zh) * 2021-02-23 2022-05-20 中山大学 一种2,2-二氟环丁烷-1-羧酸的制备方法及应用
WO2023062177A1 (en) 2021-10-15 2023-04-20 Boehringer Ingelheim International Gmbh Trpc6 inhibitory compounds for treating sepsis
JP2025023360A (ja) * 2021-12-06 2025-02-17 国立大学法人 熊本大学 Ｔｒｐｃ６の発現を抑制する方法
US20250057829A1 (en) 2023-08-18 2025-02-20 Boehringer Ingelheim International Gmbh Inhibitors of trpc6 for treating focal segmental glomerulosclerosis

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0507863A4 (en) 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
JPH06509069A (ja) 1991-06-27 1994-10-13 バージニア・コモンウェルス・ユニバーシティ シグマレセプターリガンドおよびその用途
ATE234270T1 (de) 1992-12-02 2003-03-15 Pfizer Cathecoldiether als selektive pde iv hemmungsmittel
PL346795A1 (en) 1998-09-22 2002-02-25 Yamanouchi Pharma Co Ltd Cyanophenyl derivatives
DK1259485T3 (da) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
EP1301484A2 (en) 2000-07-20 2003-04-16 Neurogen Corporation Capsaicin receptor ligands
CA2448298A1 (en) * 2001-06-15 2002-12-27 Yamanouchi Pharmaceutical Co., Ltd. Phenylpyridine carbonyl piperazine derivative
JP4186518B2 (ja) * 2001-06-15 2008-11-26 アステラス製薬株式会社 フェニルピリジン誘導体
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
DE10222291A1 (de) 2002-05-18 2003-11-27 Schlafhorst & Co W Faserbandzuführeinrichtung
CN1150176C (zh) 2002-05-22 2004-05-19 上海医药工业研究院 芳烷酮哌嗪衍生物及其应用
JP2008515972A (ja) 2004-10-13 2008-05-15 ニューロジェン・コーポレーション メラニン濃縮ホルモン受容体のリガンドとしてのアリール置換８−アザビシクロ［３．２．１］オクタン化合物
DE102005044814A1 (de) 2005-05-19 2006-11-23 Grünenthal GmbH Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DOP2006000234A (es) 2005-10-28 2007-05-31 Lilly Co Eli Inhibidores de cinasa
JP2009521448A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ
JP5019768B2 (ja) 2006-03-23 2012-09-05 独立行政法人科学技術振興機構 新規低分子化合物およびその製造方法
SG182205A1 (en) 2007-03-15 2012-07-30 Novartis Ag Organic compounds and their uses
JP5082538B2 (ja) 2007-03-28 2012-11-28 Ｄｉｃ株式会社 ピペラジン化合物
US9334242B2 (en) 2008-06-16 2016-05-10 Gtx, Inc. Compounds for treatment of cancer
US8609696B2 (en) 2008-12-18 2013-12-17 Boehringer Ingelheim International Gmbh Serotonin 5-HT2B receptor inhibitors
US20100234603A1 (en) 2009-03-13 2010-09-16 Xin Linghu Process for Making Substituted Aryl Sulfone Intermediates
US20110039850A1 (en) 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
BR112012008004A2 (pt) 2009-10-09 2016-03-29 Irm Llc compostos e composições como moduladores da atividade de gpr119
US20120232087A1 (en) 2009-11-18 2012-09-13 Silvia Buonamici Methods and compositions for treating solid tumors and other malignancies
PT2565182T (pt) 2010-04-27 2018-01-08 Mitsubishi Tanabe Pharma Corp Novo derivado de amida e a sua utilização como medicamento
AU2011253057B2 (en) 2010-05-13 2014-11-20 Amgen Inc. Nitrogen heterocyclic compounds useful as PDE10 inhibitors
AU2011283684B2 (en) 2010-07-29 2015-08-27 Rigel Pharmaceuticals, Inc. AMPK-activating heterocyclic compounds and methods for using the same
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
JP5800786B2 (ja) 2011-10-26 2015-10-28 田辺三菱製薬株式会社 新規アミド誘導体を有効成分として含有する医薬組成物
US9139585B2 (en) 2011-10-31 2015-09-22 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
CN103360343B (zh) 2012-03-30 2017-04-19 凯惠药业(上海)有限公司 一种哌嗪酰胺类化合物的制备方法
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
JP6581970B2 (ja) * 2013-05-27 2019-09-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
CN105960405B (zh) 2014-01-06 2021-02-19 理森制药股份公司 谷氨酰胺酶抑制剂
WO2015199206A1 (ja) 2014-06-27 2015-12-30 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する６員環誘導体
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
CA3001857A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
CN107176927B (zh) 2016-03-12 2020-02-18 福建金乐医药科技有限公司 组蛋白去甲基化酶lsd1抑制剂
BR112018068703B1 (pt) 2016-03-16 2024-02-06 Kura Oncology, Inc. Inibidores substituídos de menin-mll e métodos de uso
CN110337293A (zh) 2016-06-20 2019-10-15 新泽西鲁特格斯州立大学 治疗性化合物
CN107540636A (zh) 2016-06-29 2018-01-05 成都贝斯凯瑞生物科技有限公司 一种含氮杂环衍生物及其应用
CN106317050B (zh) * 2016-08-24 2018-11-23 烟台大学 一种苯基噻唑衍生物及其制备方法与应用
WO2018159827A1 (ja) 2017-03-03 2018-09-07 国立大学法人京都大学 植物ステロイドホルモン（ブラシノライド）様活性をもつ非ステロイド化合物の創製
WO2018170225A1 (en) 2017-03-15 2018-09-20 Athenex, Inc. Biaryl piperidine amide compounds and methods of use thereof
PL3786160T3 (pl) 2017-10-27 2022-10-24 Boehringer Ingelheim International Gmbh Pochodne pirydyny i ich zastosowania terapeutyczne jako inhibitory trpc6
CA3080949C (en) * 2017-11-16 2024-04-16 Principia Biopharma Inc. Immunoproteasome inhibitors
CN111770918B (zh) 2018-02-15 2024-02-27 勃林格殷格翰国际公司 Trpc6的抑制剂
EP3752503A1 (en) 2018-02-16 2020-12-23 Boehringer Ingelheim International GmbH Inhibitors of trpc6

Also Published As

Publication number Publication date
EP3786160B1 (en) 2022-07-13
HUE059450T2 (hu) 2022-11-28
US10800757B2 (en) 2020-10-13
CN111527078A (zh) 2020-08-11
AU2020250185A1 (en) 2020-11-12
PH12020550503A1 (en) 2021-03-22
LT3786160T (lt) 2022-09-26
ES2924933T3 (es) 2022-10-11
SG10202011632RA (en) 2021-01-28
CY1126109T1 (el) 2023-11-15
JP7217273B2 (ja) 2023-02-02
US20190169167A1 (en) 2019-06-06
EP3786160A1 (en) 2021-03-03
MX387232B (es) 2025-03-18
JP2021008503A (ja) 2021-01-28
WO2019081637A1 (en) 2019-05-02
ZA202002372B (en) 2023-10-25
US20210163449A1 (en) 2021-06-03
IL277493B (en) 2022-02-01
IL274039B (en) 2021-08-31
TWI780511B (zh) 2022-10-11
SI3700902T1 (sl) 2023-10-30
CN111527078B (zh) 2023-06-02
UA128474C2 (uk) 2024-07-24
MY202126A (en) 2024-04-05
PT3700902T (pt) 2023-05-30
HUE062460T2 (hu) 2023-11-28
KR102724066B1 (ko) 2024-10-30
IL274039A (en) 2020-06-30
DK3786160T3 (da) 2022-08-22
NZ763816A (en) 2025-10-31
PL3700902T3 (pl) 2023-09-04
HRP20220991T1 (hr) 2022-11-11
TW201930294A (zh) 2019-08-01
CL2020001097A1 (es) 2020-08-28
BR112020007818A2 (pt) 2020-10-20
HRP20230502T1 (hr) 2023-09-15
EP3700902B1 (en) 2023-03-08
TWI780246B (zh) 2022-10-11
SA520411843B1 (ar) 2024-01-27
LT3700902T (lt) 2023-06-26
CL2020002562A1 (es) 2021-01-15
US10889568B2 (en) 2021-01-12
AU2018355743B2 (en) 2022-04-14
ES2946274T3 (es) 2023-07-14
US20190169168A1 (en) 2019-06-06
EP3700902B8 (en) 2023-08-02
KR20200095467A (ko) 2020-08-10
AU2018355743A1 (en) 2020-05-14
AU2020250185B2 (en) 2022-04-14
KR20200125758A (ko) 2020-11-04
IL277493A (en) 2020-11-30
JP7217273B6 (ja) 2024-02-08
RS63535B1 (sr) 2022-09-30
USRE49699E1 (en) 2023-10-17
JP2021500390A (ja) 2021-01-07
MX2020004283A (es) 2021-10-21
DK3700902T3 (en) 2023-05-22
SI3786160T1 (sl) 2022-11-30
SG11202003367TA (en) 2020-05-28
PE20210154A1 (es) 2021-01-26
PT3786160T (pt) 2022-08-19
TW202120494A (zh) 2021-06-01
CA3078769A1 (en) 2019-05-02
RS64271B1 (sr) 2023-07-31
EP3700902A1 (en) 2020-09-02
JP6979502B2 (ja) 2021-12-15
FI3700902T3 (fi) 2023-05-25

Similar Documents

Publication Publication Date Title
HUE059450T2 (hu) Piridin származékok és ezek terápiás alkalmazásai TRPC6 inhibitorokként
IL253712B (en) Mysterlein derivatives for coupling and healing
IL258978B (en) The use of pyrimidine and pyridine derivatives in the treatment of multiple sclerosis
PL3287443T3 (pl) 6-członowa pochodna heterocykliczna i kompozycja farmaceutyczna ją zawierająca
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
SMT202400335T1 (it) Derivati di amminopiridina e loro uso come inibitori selettivi di alk-2
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
IL274722A (en) History of pyridinones and their use as selective inhibitors of ALK-2
ZA201705530B (en) 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors
IL261645A (en) History of dioxo-hexahydroisoindolyl and their use as cyclophilin inhibitors
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
EP3253734A4 (en) Glucosylceramide synthase inhibitors and therapeutic methods using the same
ZA202000959B (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
IL261644A (en) Oxalyl derivatives and their use as cyclophilin inhibitors
HK40029730A (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
HK40007022A (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors